Date Updated September 27, 2019

UNIVERSITY OF COLORADO SCHOOL OF MEDICINE

CURRICULUM VITAE

Name: Mark Patrick Steele, M.D., F.C.C.P.

Office Address: L15-7517, Academic Office 1
12631 E. 17th Ave
Aurora, CO 80045

E-Mail Address: mark.steele@cuanschutz.edu

Education:

08/74-06/78 University of Illinois, Champaign-Urbana, Illinois, B.S., Physiology

07/78-06/82 University of Illinois College of Medicine, Chicago, Illinois, M.D.

07/82/-06/83 Intern, Internal Medicine, University of Illinois College of Medicine and West Side Veterans Administration Hospital, Chicago, Illinois

07/83-06/85 Assistant in Medicine (Resident), University of Illinois College of Medicine and West Side Veterans Administration Hospital, Chicago, Illinois

07/85-06/86 Instructor in Medicine, University of Illinois College of Medicine, Chicago, Illinois

07/85-06/86 Chief Resident in Medicine, University of Illinois College of Medicine, Chicago, Illinois

07/86-06/90 Postdoctoral Fellow, Pulmonary Medicine, Boston University School of Medicine, Boston, Massachusetts (Rotations included Boston University Pulmonary Center, University Hospital, Boston City Hospital, Boston VA Hospital)

07/90-07/92 Assistant in Medicine, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University College of Medicine, Durham, North Carolina

Academic Appointments:

07/90-07/92 Assistant in Medicine, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University College of Medicine, Durham, North Carolina

08/92-12/95 Assistant Professor of Medicine, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University College of Medicine, Durham, North Carolina

01/96-07/97	Clinical Assistant Professor of Medicine, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina [clinical practice at Carolinas Medical Center]
08/97-10/03	Assistant Clinical Professor of Medicine, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University College of Medicine, Durham, North Carolina
11/03-11/11	Associate Clinical Professor of Medicine, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University College of Medicine, Durham, North Carolina
08/04-2/12.	Clinical Faculty – Type A, Duke Clinical Research Institute, Durham, North Carolina
11/11-2/12.	Clinical Professor of Medicine, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University College of Medicine, Durham, North Carolina
3/12-4/16	Professor of Medicine, Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine
5/16-3/18	Staff Physician, Charlotte Veterans Administration Healthcare Center, Director, Pulmonary Outpatient Clinic
4/18-	Visiting Professor of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Anschutz Medical Campus.

Hospital Appointments:

07/88-06/90	Attending Physician, Pulmonary Consultant-Chronic Ventilator Unit, Jewish Memorial Hospital, Boston, Massachusetts
10/88-06/90	Attending Physician, Pulmonary Consultant, Carney Hospital, Boston, Massachusetts
07/89-06/90	Attending Physician, Pulmonary Consultation and Bronchoscopy Services, Boston City Hospital, Boston, Massachusetts
07/90-12/95	Attending Physician and Pulmonary Consultant in Critical Care, Bronchoscopy Service, Duke University Medical Center and Department of Veterans Affairs Medical Center, Durham, North Carolina
07//90-12/95	Attending Physician, General Medical Service, Department of Veterans Affairs Medical Center, Durham, North Carolina

07/92-12/95	Director, Pulmonary Outpatient Clinics, Department of Veterans Affairs Medical Center, Durham, North Carolina
07/94-06/95	Attending Physician, Residents in Medicine Outpatient Clinic, Duke University Medical Center, Durham, North Carolina
01/96-07/97	Co-Director, Asthma Initiative, Carolinas Medical Center, Charlotte, North Carolina
01/96-07/97	Staff Physician, Medical Intensive Care Unit, Carolinas Medical Center, Charlotte, North Carolina
01/98-12/03	Director, Pulmonary Inpatient Service, Duke University Medical Center, Durham, North Carolina
07/99-07/03	Director, Pulmonary Bronchoscopy Service, Duke University Medical Center, Durham, North Carolina
3/12-04/16	Medical Director, Vanderbilt Lung Transplant Program
05/16-3/18	Staff Physician, Medicine Service, Salisbury VA Med Ctr and Charlotte Health Care Center. Medical Director, Pulmonary Outpatient Services, Charlotte HealthCare Center, Charlotte, NC.
04/18-	Attending Physician, University of Colorado Health, Univ. of Colorado Lung Transplant Program

Honors, Special Recognitions, and Awards:

Phi Kappa Phi, 1978
James Scholar ,1976-78
MD with Honors, 1982
Scott Venerable American Thoracic Society of North Carolina Research Award, 1992

Membership in Professional Organizations:

1986-1990	Member, Massachusetts Medical Society
1996-Pres.	Fellow, American College of Chest Physicians
1987-Pres.	Member, American Thoracic Society
2001-Pres.	Member, International Society for Heart and Lung Transplantation
2005-2006	Member, Clinical Practice Committee, American Thoracic Society

Major Committee and Service Responsibilities:

Intramural:

(School or University Committees, inclusive dates)

07/85-06/86 Conference Coordinator, Clinical Pathologic Conference and Medical Grand Rounds, University of Illinois Hospital

09/90/12/95 Coordinator, Visiting Pulmonary Scholars Program, Duke University College of Medicine

07/98-06/03 Director of Pulmonary Fellowship Recruitment, Duke University College of Medicine, Durham, North Carolina

2007-2012. Committee Member, Institutional Review Board, Duke University College of Medicine, Durham, North Carolina

Extramural:
(Study groups, site visits, government agencies or private organizations, including offices held with inclusive dates, editorial appointments, ad hoc reviewing)

Consultant Appointments:

Astra-Zeneca Pain Advisory Committee for Critically Ill Patients
InterMune Advisory Panel on the Treatment of IPF with Interferon Gamma
Speakers Bureau, Glaxo Smith Kline, Astra Zeneca, Merck Medco

Licensure and Certification:

Medical License:
North Carolina, 1990-Current
Tennessee, 2012-Current
Colorado, 2018- Current

American Board of Internal Medicine
Internal Medicine 09/11/85 # 105205
Pulmonary Medicine 11/01/88 # 105205
Critical Care Medicine, 11/01/90 # 105205 - Recertification 11/01/00, 11/01/2014

07/02-06/04 Medical Genomics Training Program, Duke Clinical Research Institute, Durham, North Carolina

1984-1986 Certified Instructor, Advanced Cardiac Life Support, Chicago Heart Association

Review and Referee Work

Ad hoc reviewer, CHEST, 2006- current.
Ad hoc reviewer, American Journal Respiratory and Critical Care, 2006-current.

Ad hoc reviewer, PlosOne, 2009-current.
Ad hoc reviewer, BMC Genomics, 2011-current.

Invited extramural lectures, presentations, and visiting professorships:

Invited Speaker: "Idiopathic Pulmonary Fibrosis: Staging and Management." American Thoracic Society Meeting, Denver, Colorado, May 13-18, 2011.

Invited Speaker: "Familial Interstitial Pneumonias." 5th International WaSOG Conference on Diffuse Lung Disease, Charleston, South Carolina, May 2009.

Invited Speaker: "The Genetics of Familial Pulmonary Fibrosis," Visiting Professor, Medical University of South Carolina, Charleston, South Carolina, April 2007.

Invited Lecturer: "Genetic Approaches to Pulmonary Fibrosis." American Thoracic Society Post-Graduate Course, San Diego, California, May 20-25, 2005.

Lecturer: "The Search for Genes in Pulmonary Fibrosis." American College of Chest Physicians Post-Graduate Course, American College Chest Physicians Annual Meeting, San Diego, California, October 2002.

Invited Speaker: "Lung Transplantation for the Treatment of Pulmonary Fibrosis: A patient's perspective". Coalition for Pulmonary Fibrosis, Duke University Medical Center,

Invited Speaker: "Advances in Idiopathic Pulmonary Fibrosis"/. Pulmonary Division, University of Louisville, Louisville, KY, October, 2005

Session Facilitator: "Clinical Case Presentations". American Thoracic Society Annual Meeting, Denver, CO, May 2011.

Session Facilitator: " Clinical Interstitial Lung Disease". American Thoracic Society Annual Meeting, San Diego, CA, 2009.

Invited Speaker: "Is Idiopathic Pulmonary Fibrosis really Idiopathic ?" Pulmonary Division Grand Rounds, Emory University, Atlanta, GA, August 2011

Invited Speaker: "When it is not IPF: Familial Interstitial Pneumonia". American Thoracic Society Annual Meeting, San Francisco, CA, May 2012.

Invited Speaker: "Beyond Emphysema and IPF", Vanderbilt Thoracic Symposium, Nashville, TN, April 2012

Invited Speaker. "Evolving approaches to diagnosing IPF: Genetic Screening, transbronchial cryobiopsy, and multidisciplinary review." American Thoracic Society Annual Meeting, Philadelphia, PN, May 2013

Invited Speaker. "Familial Interstitial Pneumonia: Clinical Evaluation":. American Thoracic Society Annual Meeting, San Diego,. CA, May 2014

Teaching Activities:

Teaching responsibilities including continuing education:

Medical School Courses
Coarse Title: Introduction to Physical Diagnosis, 1998, 1999 Boston University School of Medicine Lecturer
Role of Candidate: Demonstration of Physical Exam of Respiratory System
Required Course: Yes
Contact Hours: 1 hour /week for 4 weeks during Respiratory Medicine module.

Course Title: Biology of Disease; 1998, 1999. Pulmonary Medicine for Core Clerkship in Medicine, Boston University School of Medicine
Role of Lecturer: Assistant Lecturer, Clinical Case Discussions
Required Course: Yes
Contact Hours: 1 hour/week for 8 weeks for Core Clerkship in Medicine

Coarse Title: Pathophysiology and Medical Therapeutics, 2001, 2002, 2003
Role of Candidate: Primary Lecturer, Interstitial Lung Disease
Required Course: No
Contact Hours: One 2 hour lecture annually in August

Physician Assistant Courses
Coarse Title: Lower Respiratory Tract Infections, 2002-2005. Duke University School of Medicine
Role of Candidate: Primary Lecturer
Required Course: Yes
Contact Hours: 3 hour lecture annually in January.

Coarse Title: Interstitial and Environmental Lung Disease, 2010, Duke University School of Medicine
Role of Candidate: Primary Lecturer
Required Course: Yes
Contact Hours: 3 hour lecture annually in January

Pulmonary and Critical Care Fellowship Training Program, Duke University Medical Center
Course Title: Ambulatory continuity Pulmonary Clinic, Durham VA Medical Center, 1990-95.
Role of Candidate: Preceptor
Required Course: Yes
Contact Hours: 4 hours/day 1 day a week for 48 weeks/year, supervise 4 pulmonary fellows

Course Title: Ambulatory continuity Pulmonary Clinic, Duke Clinic, 1997-2005.
Role of Candidate: Preceptor
Required Course: Yes
Contact Hours: 4 hours/day 1 day a week for 10 weeks/year, supervise 4 pulmonary fellows

Didactic Lecturer Series, Pulmonary and Critical Care Fellowship Program, Duke University Medical Center, 2000-present. : Dr. Steele is primary lecturer for weekly noon lectures to pulmonary fellows on various pulmonary topics primarily in the areas of 1) Interstitial Lung Disease, 2) Diagnostic Fiberoptic ,and 3)Lung Transplantation. One lecture every 3-4 months annually.

Trainees (representative)

Rodney Folz, MD, PhD.
Postdoctoral Fellow 1992-1994
Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University
Current Position. Professor of Medicine, Chief, Division of Pulmonary and Critical Care, University of Louisville.,
Activities: Dr. Steele provided mentoring to Dr. Folz in basic research related to the molecular biology of superoxide dismutase after Dr. Folz completed his clinical training.

Momen Wahidi, MD
Postdoctoral Fellow 1999-2002
Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University
Current Position. Associate Professor of Medicine, Medical Director, Interventional Pulmonary Program, Duke University Medical Center
Activities: Dr. Steele provided mentored Dr. Wahidi in bronchoscopy training and clinical research in the genetics of pulmonary fibrosis.

David Zaas, MD, MBA
Postdoctoral Fellow 2001-2005
Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University
Current Position. Assistant Professor of Medicine, Vice Chairman of Clinical Affairs, Department Medicine, Duke University, Prior Medical Director of Duke Lung Transplant Program
Activities: Dr. Steele provided mentoring and focused training to Dr. Zaas in the subspecialty of Lung Transplantation.

Alice Gray, MD
Postdoctoral Fellow 2006-2010
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University.
Current Position. Assistant Professor of Medicine, Duke University.
Activities: Dr. Steele provided mentoring and focused training to Dr. Zaas in the subspecialty of Lung Transplantation.

Dennis Hadjiliadis, MD, MHS
Postdoctoral Fellow 2000-2001
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University.
Current Position. Assistant Professor of Medicine, Duke University.
Activities: Dr. Steele provided mentoring and focused training to Dr. Hadkiliadis in the subspecialty of Lung Transplantation

Laurie Snyder, MD
Postdoctoral Fellow 2006-2010
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University.
Current Position. Assistant Professor of Medicine, Duke University.
Activities: Dr. Steele provided mentoring and focused training to Dr. Snyder in the subspecialty of Lung Transplantation

Teresa Martinu, MD
Postdoctoral Fellow 2007-2008
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University.
Current Position. Assistant Professor of Medicine, Duke University.
Activities: Dr. Steele provided mentoring and focused training to Dr. Martinu in the subspecialty of Lung Transplantation.

Rob Tighe
Postdoctoral Fellow 20009-2010
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University.
Current Position. Associate of Medicine, Duke University.
Activities: Dr. Steele provided mentoring and focused training to Dr. Tighe in the subspecialty of Interstitial Lung Disease

Anita Reddy, MD
Postdoctoral Fellow 2006-2007
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University.
Current Position. Dr Reddy is now Associate Staff at Cleveland Clinic.
Activities: Dr. Steele provided mentoring and focused training to Dr. Reddy in the subspecialty of Interstitial Lung Disease and Lung Transplantation.

Stephanie Norfolk, MD
Postdoctoral Fellow 20010-2011
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University.
Current Position. Associate of Medicine, Duke University.
Activities: Dr. Steele provided mentoring and focused training to Dr. Norfolk in the subspecialty of Lung Transplantation.

Ciara Shaver, MD, PhD
Postdoctoral Fellow 20113-2014
Division of Allergy, Pulmonary, Critical Care Medicine, Department of Medicine, Vanderbilt University
Current Position: Postdoctoral Fellow, Division of Allergy, Pulmonary, Critical Care Medicine, Department of Medicine, Vanderbilt University

Activities: Dr. Steele provided mentoring and focused training to Dr. Shaver in the subspecialty of Lung Transplantation

Funded Research

NIH or Government Funded Projects:

Active Projects

DoD W81XWH-17-1-0597 (PI: Schwartz) 09/30/17-09/29/21 3.6 calendar mo.
Department of Defense – Program Project Idiopathic Pulmonary Fibrosis, a disease initiated by mucociliary dysfunction .
The overall goal of this Program Project is to build on our knowledge of IPF, the *MUC5B* promoter variant rs35705950, and mucin biology to develop the scientific basis to predict, detect, and prevent the progression of preclinical pulmonary fibrosis before extensive scarring and fibrosis occurs.

Completed Projects

5 U10 HL 080413-05 (PI: Anstrom) 05/01/05 - 04/30/10 1.20 calendar months
NIH/NHLBI $4,599,862
"Idiopathic Pulmonary Fibrosis Clinical Research Network"
Role: Co-Investigator on the Data Coordinating Center
This program will efficiently conduct randomized trails to improve clinical outcomes for patients with newly diagnosed idiopathic pulmonary fibrosis (IPF).

1 RC1 HL 099571-01 (PI: Steele) 09/30/09 - 09/29/11 10.56 calendar months
NIH/NHLBI $387,338
"Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia"
The overall goal of the proposed project is to develop and validate molecular signatures in the peripheral blood that serve to refine the diagnostic criteria for this group of complex diseases.

5 R01 HL 097163-03 (PI: Schwartz) 09/03/09 - 07/31/14 1.87 calendar months
Consortium with National Jewish Health – Denver $110,626
"GWAS in Fibrosing Interstitial Lung Disease"
Role of Dr. Steele: Site PI
The purpose of this project is to discover genes and gene variants that are central to the development of fibrosing interstitial lung diseases (fILD).

5 P01 HL 092870-02 (Schwartz) 11/01/09 - 10/30/14 2.40 calendar months
National Jewish Medical and Research Center $12,577
"Gene and Environment interactions in Pulmonary Fibrosis"
Role of Dr. Steele: Site PI
The overall goal of this proposal is to discover genetic variants that are central to the development of idiopathic interstitial pneumonia (IIP).

5 P01 HL 092870-02 (Blackwell) 1/19/10 - 12/31/14 0.24 calendar months
NIH/NHLBI $19,640 (Consortium)
"Mechanisms of Familial Pulmonary Fibrosis"
Role of Dr. Steele: Co-Investigator, Core B
We intend to use a unique cohort of families with FIP to investigate the underlying mechanisms that lead to progressive lung fibrosis. This information will be highly relevant to individuals with sporadic idiopathic pulmonary fibrosis (IPF) and other forms of interstitial lung disease. The large cohort of families with FIP assembled by our group provides a new opportunity to define the mechanisms of progressive pulmonary fibrosis. Genetic information from these families has already begun to revolutionize research in this area. We believe that knowledge gained by further studying individuals in families with FIP will lead to new and effective therapies for IPF and related interstitial lung diseases. Three projects are supported by two cores. This program includes collaboration with the University of Colorado Health Science Center and Jewish Hospital in Denver, Colorado, and Duke University in Durham, North Carolina.
The goal of Core B is to recruit patients and members of families with IPF, and sporadic IPF patients, to characterize the phenotypes and obtain the specimens needed to conduct all studies of the program, with the central overall objective to understand the genetic and environmental mechanisms that contribute to IPF.

IPA 03/01/06 – 02/28/08
Principal Investigator: M. Steele
NIH/NIEHS
Institutional Support
"Oversees All Aspects of the Familial Pulmonary Fibrosis Study at the NIEHS RTP Site"

Genetic Determinants of Pulmonary Fibrosis 2000-2005
Principal Investigator: David A. Schwartz
Coinvestigator: M. Steele
NIH/NHLBI The clinical and demographic features of familial interstitial pneumonia in the U.S was demonstrated to be a late-onset, male-predominate disease, and consistent with autosomal dominant inheritance with reduced penetrance. Significant phenotypic variation with families and environmental association with cigarette smoking was demonstrated. Linkage peaks were identified on chromosomes 10, 11, and 12

Research Advisory Group Award 1990-1992
Veterans Administration
Principal Investigator: M. Steele
Characterization of Differentiation-related Genes in Alveolar Type 2 Epithelial Cells

Clinical Investigator Award, NHLBI K08 HL002620 1991-1995
Principal Investigator: M. Steele
"Characterization of Differentiation-Related Genes in Alveolar Type 2 Epithelial Cells". These studies identified several genes to be preferentially expressed in alveolar type 2 cells including clara cell secretory protein, spectrin, and a gene with unknown function.

Private Foundation or Industry Funded Projects:

GIPF 007 04/15/04 – 12/31/07
Principal Investigator: M. Steele
InterMune Pharmaceuticals, Inc. (INSPIRE)
"A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Interferon Gamma-1b (IFN-y1b) in Patients with Idiopathic Pulmonary Fibrosis". Interferon-gamma was found not to be effective in the treatment of Idiopathic Pulmonary Fibrosis

GIPF 006 03/15/06 – 12/31/07
Principal Investigator
InterMune Pharmaceuticals, Inc. (CAPACITY)
"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis". Pirfenidone was identified to be effective in a subset of patients with Idiopathic Pulmonary Fibrosis. Based on this study, in order to secure FDA approval, a larger multi-national clinical trial is currently in progress.

Biogen, Inc. C97-829 06/28/00 - 02/21/01
Principal Investigator: M. Steele
"The efficacy of Avonex (Interferon beta 1-a) in the Treatment of Idiopathic Pulmonary Fibrosis"
The purpose of the study is to determine the effect of AVONEX (a recombinant form of human interferon beta-1a, an anti-inflammatory agent) on the symptoms of IPF. Interferon-beta was found not to be effective in the treatment of Idiopathic Pulmonary Fibrosis

InterMune GIPF-001 02/01/01 - 07/01/02
Principal Investigator: M. Steele
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-γ 1b(rIFN-γ 1b) in Patients with Idiopathic Pulmonary Fibrosis.
The primary objective of this study is to determine the time to first occurrence of disease progression or death in patients with idiopathic fibrosis (IPF). The hypothesis to be tested is if Interferon-γ 1b (Actimmune® will decrease the loss of pulmonary function in patients with IPF.

InterMune GIPF-004 11/1/02-2004
Principal Investigator: M. Steele
Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Continuation of GIPF-001

American Lung Association of North Carolina, Research Award 1991-1992
Characterization of Differentiation-Related Genes in Alveolar Type 2 Epithelial Cells

Bibliography:

Journal Articles:

1. Clement A, **Steele MP**, Brody JS, Reidel N. Growth-related gene expression in alveolar type II epithelial cells. *Am Rev Respir Dis*. 142S:S60-S62, 1990.

2. Clement A, **Steele MP,** Brody JS**,** Reidel N. Simian Virus 40 Large T-immortalized lung alveolar epithelial cells display post-transcriptional regulation of proliferation-related genes. *Exp Cell Res*. 196:198-205, 1991.

3. Joyce-Brady M, Rubin JB, Panchenko MP, **Steele MP,** Bernardo J, Simons ER, Brennan L, Kolan L, Dickey BF. Mechanisms of mastoparan-stimulated surfactant secretion in isolated pulmonary alveolar type II cells. *J Biol Chem*. 266(11):6859-6865, 1991.

4. **Steele, MP,** Levine, RH, Brody, JS. A rat alveolar type II cell line generated by adenovirus 12SE 1A gene transfer. *Am J Respir Cell Mol Biol*. 6:50-56, 1992.

5. Ghio Andrew J, Stonehuerner J, **Steele MP**, Crumbliss AL. Phagocyte-generated superoxide reduces Fe3+ to displace it from the surface of asbestos. *Arch Biochem Biophys*. 315(2):219-225, 1994.

6. Matsui R, Goldstein RH, Mihal K, Brody JS, **Steele MP**, Fine A. Type I collagen formation in rat type II alveolar cells immortalized by viral gene products. *Thorax*. 49(3):201-206, 1994.

7. Zhao Y, Young SL, McIntosh JC, **Steele MP,** Silbajoris R. Ontogeny and localization of TGF-ß type I receptor expression during lung development. *Am J Physiol Lung Cell Mol Physiol*. 278(6):L1231-L1239, 2000.

8. O'Regan A, Felon HM., Beamis JF, **Steele MP**, Skinner M, Berk JL. Tracheobronchial amyloidosis. *Medicine*. 79(2):69-79, 2000.

9. Wahidi MM, Speer MC, **Steele MP**, Brown KK, Schwarz MI, Schwartz DA. Familial pulmonary fibrosis in the United States. *Chest*. 121:(3 Suppl.):30S, 2002.

10. Davis RD, Lau CL, Eubanks E, Messier RH, Hadjiliadis D, **Steele MP**, Palmer SM. Improved lung allograft function following fundoplication in lung transplant patients with GERD. *J Thorac Cardiovasc Surg.* 125(3):533-542, 2003.

11. Hadjiliadis D, Davis RD, **Steele MP,** Messier RH, Lau CL, Eubanks SS, Palmer SM. Gastroesophageal reflux disease in lung transplant recipients. *Clin Transplant.* 17(4):363-368, 2003.

12. Reams BD, McAdams HP, Howell DN, **Steele MP**, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder (PTLD): incidence, presentation, and response to treatment in 400 lung transplant recipients. *Chest*. 124(4):1242-1249, 2003.

13. Palmer SM, Grinnan DC, Reams BD, **Steele MP**, Messier RH, Davis RD. Delay of CMV infection in high risk CMV mismatch lung transplant recipients due to prophylaxis with oral Ganciclovir. *Clin Transplant.* 18:179-185, 2004.

14. Hadjiliadis D, **Steele MP,** Govert JA, Davis RD, Palmer SM. Outcome of lung transplant patients admitted to the Medical ICU. *Chest.* 125(3):1040-1045, 2004 **(with accompanying editorial).**

15. Lodge BA, Ashley, ED, **Steele MP**, Perfect, JR. *Aspergillus fumigatus* empyema, arthritis and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. *J Clin Microbiol.* Mar 42(3):1376-1378, 2004.

16. Garantziotis S, **Steele MP**, Schwartz, DA. Pulmonary fibrosis: thinking outside the lung. *J Clin Invest.* 114(3):319-321, 2004.

17. Hadjiliadis D, Chaparro C, Reinsmoen NL, Gutierrez C, Singer LG, **Steele MP**, Waddell TK, Davis RD, Hutcheon MA, Palmer, SM, Keshavjee S. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multi-center study. *J Heart Lung Transplant*. 24(7 Suppl):S249-S254, 2005.

18. **Steele MP**, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi MM, Phillips JA, Sporn TA, McAdams HP, Schwarz MI, Schwartz DA. Clinical and pathologic features of familial interstitial pneumonia. *Am J Respir Crit Care Med*. 172(9):1146-1152, 2005.

19. Palmer SM, Davis RD, Simsir SA, Lin SS, Harwig M, Reidy MF, **Steele MP**, Eu PC, Blumenthal JA, Babyak MA. Successful bilateral lung transplant outcomes in recipients 61 years of age and older. *Transplantation.* 81(6): 862-865, 2006.

20. Hadjiliadis D, Chaparro C, Gutierrez C, **Steele MP**, Singer LG, Davis RD, Waddell TK, Hutcheon A, Palmer SM, Keshavjee, S. Impact of lung transplant operation on bronchiolitis obliterans syndrome in patients with chronic obstructive pulmonary disease. *Am J Transplant*. 6(1):183-189, 2006.

21. Roggli VL, Piantadosi CA, MacIntyre NR, Young SL, Kussin PS, **Steele MP**, Carraway MS, Welty-Wolf KE, Govert JA, McMahon TJ, Palmer SM, Sporn TA, Ghio AJ. Physician subsidies for tobacco advertising. [lett.] *Am J Respir Crit Care Med.* 173(2):246, 2006.

22. **Steele MP**, Speer MC, Loyd JC, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi M, Phillips JA, Sporn TA, McAdams HP, Schwarz MI, Schwartz DA. The role of genetics and cigarette smoking in the development of pulmonary fibrosis. *Respirology*. 1:S23, 2006.

23. Yang IV, Burch LH, **Steele MP**, Savov JD, Hollingsworth JW, McElvania-Tekippe E, Berman KG, Speer MC, Sporn TA., Brown KK, Schwarz MI., Schwartz DA. Gene expression profiling of familial and sporadic interstitial pneumonia. *Am J Respir Crit Care Med*. 175:45-54, 2007.

24. Hadjiliadis, D, **Steele MP**, Chaparro C, Singer LG, Waddell TK, Hutcheon MA, Davis RD, Palmer SM. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. *J. Heart and Lung Transplantation*. 26(8):834-838, 2007.

25. Martinu T, Howell DN, Davis RD, **Steele MP**, Palmer SM. Pathological correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. *Chest.* 129(4):1016-1029, 2006.

26. Reams BD, Musselwhite L, Zaas DW, **Steele MP**, Garantzioitis S, Eu PC, Snyder LD, Curl J, Lin SS, Davis RD, Palmer SM. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. *Am J Transplant*. 7:2802-2808, 2007.

27. Sathy SJ, Martinu T, Youens K, Lawrence CM, Howell D, Palmer SM, **Steele MP.** Symptomatic Pulmonary Kaposi's Sarcoma in two lung transplant recipients. *Am J Transplantation*. 8:1951-1956, 2008.

28. Boon K, Bailey NW, Tomphor JK, **Steele MP**, et al. Molecular phenotypes distinguish patients with relatively stable from progressive Idiopathic Pulmonary Fibrosis (IPF). *PLoS One* 4(4):e5134, 2009.

29. The Idiopathic Pulmonary Fibrosis Research Network [includes **Dr. Mark Steele**]. A controlled trial of sildenafil in advanced Idiopathic Pulmonary Fibrosis. *NEJM*. 363:620-628, 2010.

30. Seibold MA, Wise AL, Speer MC, **Steele MP**, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, DuBois RM, Yang IV, Brodie A, Kervitsky D, Talbert JL, Markin C, Park J, Crews AL, Slifer SH, Auerbach S, Roy MG, Lin J, Hennessy CE, Schwarz MI, Schwartz DA. A common polymorphism in the promoter of MUC5B is associated with familial interstitial pneumonia (FIP) and idiopathic pulmonary fibrosis (IPF). *NEJM*. 364:1503-1512, 2011.

31. Meltzer EB, Barry WT, D'Amico TA, Davis RD, Lin SS, Onaitis MW, Morrison LD, Sporn TA, **Steele MP**, Noble PW. Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle. *BMC Med Genomics*. 4:70, 2011.

32. Leslie KO, Cool CD, Sporn TA, Curran-Everett D, **Steele MP**, Brown KK, Wahidi MM, Schwartz DA. Familial Idiopathic Interstitial Pneumonia; Histopathology and Survival in 30 patients. *Arch Path Lab Med*. 136:1366-1376, 2012.

33. The Idiopathic Pulmonary Fibrosis Research Network [includes Steele MP]. Prednisone, azathioprine, and N-acetylcysteine for Pulmonary Fibrosis. *NEJM,* 353:366-372, 2012

34. Peljto AL, **Steele MP**, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, Carns M, Schwarz M, Varga J, Schwartz DA. The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis. *Chest*. 142: 1584-1588, 2012.

35. Lee HY, Seo JB, **Steele MP**, Brown KK, Loyd JL, Schwarz MI, Brown KK, Loyd JL Schwartz DA, Talbert JL, Lynch DA. High-Resolution CT Findings in Familial Interstitial

Pneumonia Do Not Conform to Those of Idiopathic Interstitial Pneumonia. *Chest*. 142:1577-1583, 2012.

36. Yang IV, Luna LG, Cotter J, Talbert J, Leach SM, Kidd R, Turner J, Kummer N, Kervitsky D, Brown KK, Boon K,Schwarz MI, Schwartz DA**, Steele MP**. The Peripheral Blood Transcriptome Identifies the Presence and Extent of Disease in Idiopathic Pulmonary Fibrosis. *PlosOne.* 7(6): e37708, 2012.

37. Huninghake GM, Hatabu H. Okajima Y, Dupuis J, Nishina M, Kurugol S, Ross JC, Estepar RS, Murphy E, **Steele MP**, Loyd JE, Schwarz MI, Fingerlin TE, Rosas IO, Washko GR, O'Connor GT, Schwartz DA. MUC5B promoter polymorphism (rs35705950) is predictive of interstitial lung abnormalities in the general population. *NEJM*. 368:2192-2000, 2013.

38. Zhang Y, Schwarz MI, Richards TJ, Silveira LJ, Fingerlin TE, Peljto AL, Lindel KO, **Steele MP**, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Murphy, E, Kaminski N, Schwartz DA. MUC5B, a genetic determinant of survival in idiopathic pulmonary fibrosis. *JAMA*. 309:2232-2239. 2013

39. Tasha E. Fingerlin, Elissa Murphy, Weiming Zhang, Anna L. Peljto, Kevin K. Brown, **Mark P. Steele**, James E. Loyd, Gregory Cosgrove, David Lynch, Steve Groshong, Harold R. Collard, Williamson Z. Bradford, Keith Smith, Roland M. du Bois, Christine Garcia, Gunnar Gudmundsson, Naftali Kaminski, Lisa H. Lancaster, Toby Maher, Philip L. Molyneaux, Moises Selman, James D. Crapo, David McKean, Janet Talbert, Cheryl Walke, Dinesha S. Walek, Jerry J. Daniel, Kenneth B. Beckman, Mark Lathrop, Marvin I. Schwarz, David A. Schwartz. Pulmonary Fibrosis is a genetic disorder caused by multiple genetic risk loci. *Nature Genetics* (epub 4.24.13).2013

40. Kropski JA, Pritchett JM, Mason WR, Sivarajan L, Gleaves LA, Johnson JE, Lancaster LH, Lawson WE, Blackwell TS, **Steele MP**, Loyd HE, Rickman OB. Bronchoscopic Cryobiopsy for the Diagnosis of Diffuse Parenchymal Lung Disease. *PlosOne*. 8(11):e78674. 2013

41. Meltzer EB, Barry WT, Yang IV, Brown KK, Schwarz MI, Patel H, Ahley A, Noble PW, Schwartz DA, **Steele MP**. Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood. *BMC Genomics.* 15:902.2014

42. Kropski JA, Pritchett JM, Zoz DF, Crossna PF, Markin C, Garnett ET, Degryse AL, Mitchell DM, Polosukhin VV, Rickman OB, Choi L, Cheng DS, McConaha ME, Jones BR, Gleaves LA, Worrell JA, Solus JF, Ware LB, Stein CM, Lee JW, Massion PP, Zaynagetdinov R, White ES, Johnson JE, Groshong SD, Lancaster LA, Young LR, **Steele MP**, Phillips JA, Cogan JD, Loyd JE, Lawson WE, Blackwell TS. Extensive phenotyping of individuals at risk for Familial Interstitial Pneumonia reveals clues to the pathogenesis of interstitial lung disease. *AJRespirCritCareMed.*191:417-426. 2015.

43. Cogan JD, Kropski JA, Zhao M, Mitchell DP, Rives L, Markin C, Garnett ET, Montgomery KH, Mason WR, McKean DE, Powers J, Murphy E, Olson LM, Choi L, Young LR, Lancaster LH, **Steele MP**, Fingerlin TE, Schwarz MI, Schwartz DA, Lawson WE, Loyd JE, Zhao Z, Phillips JA, Blackwell TS. Heterozygous mutations in RTEL1 are associated with familial interstitial pneumonia. *AJRespirCritCareMed.* 191:646-655. 2015.

44. Kim, SY, Diggans J, Pankratz D, Huang J, Pagan M, Sindy N, Tom E, Anderson J, Choi Y, Lynch D, **Steele MP**, Flaherty KR, Brown KK, Farah H, Bukstein MJ, Pardo A, Selman M, Wolters PJ, Nathan SD, Colby TV, Katzenstein AL, Raghu G, Kennedy GC. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. *LancetRespirMed,* 3:473-482. 2015.

45. **Steele MP**, Luna LG, Coldren CD, Murphy E, Hennessey CE, Heinz D, Evans CM, Groshong S, Cool C, Cosgrove GP, Brown KK, Fingerlin TE, Schwarz MI, Schwartz DA, Yang IV. Relationship between gene expression and lung function in Idiopathic Interstitial Pneumonia. *BMC Genomics* 15: 869-73. 2015.

46. Mathai SK, Pedersen BS, Smith K, Russell P, Schwarz MI, Brown KK, **Steele MP**, Loyd JE, Crapo JD, Silverman EK, Nickerson D, Fingerlin TE, Yang IV, Schwartz DA. Desmoplakin Variants are associated with Idiopathic Pulmonary Fibrosos. *AmJRespCritCareMed* 15:1151-1160. 2016.

47. Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, **Steele MP**, Loyd JP, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PG, Bradford WZ, Kossen K, Swiwert SD, du Bois, RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatina Y, Zelenika D, Murphy E, Smith K, McKean D. Pedersen BS, Talbert J, Posers J, Markin CR, Beckman KM, Lathrop M, Freed B. Langefeld CD, Schwartz DA. Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. *BMC Genet.* 17: 74, 2016.

48. Pankratz DG, Choi Y, Imtiaz U, Fedorowicz GM, Anderso JD, Colby TV, Myers JL, Lynch DA, Brown KK, Flaherty KR, **Steele MP**, Groshong SD, Raghu G, Barth NM, Sean PW, Huang J, Kennedgy GC, Martinez FJ. Usual Interstitial Pneumonia can be detected in transbronchial biopsies using machine learning. *Ann Am Thoracic Soc.* June 22, 2017. PM ID 28640655.

49. Raghu G, Flaherty KR, Lederer DJ, Lynch DA, Colby TA, Myers JL, Larsen BT, Chung JH, **Steele MP,** et al. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial biopsy samples: a prospective validation study. *The Lancet. Respiratory Medicine*. In press: April 01, 2019 https://doi.org/10.1016/S2213-2600(19)30059-1.

50. Moore C, Blumhagen RZ,Yang IV,Walts A, Powers J,Walker T,Bishop M, Russell P, Vestal B, Cardwell J, Markin CT,Matha SK,Schwarz MI, **Steele MP**, et al. Resequencing Study Confirms Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. *Am J Resp Crit Care Med*. 200:199-208, 2019. PM ID 31034279.

51. Mathai SK, Humphries S, Kropski JA, Blackwell TA, Powers J, Walts AD, Markin C, Woodward J, Chung JH, Brown KK, **Steele MP**, Loyd JE, Schwarz MI, Fingerlin T, Yang IV, Lynch DA, Schwartz DA. *Muc5B* variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis. *Thorax.* 74:1131-1139, 2019. PM ID 31558622.

Books and Book Chapters:

1. Brody JS, Joyce-Brady M, Steele MP. Growth and differentiation of pulmonary alveolar epithelial cells. In: *Respiratory Epithelium*. P Nettesheim, DG, Thomassen, Eds., Academic Press, 1991, pp. 60-66.

2. Steele MP, Peterson MW, Schwartz DA: Asbestosis and asbestos-induced pleural fibrosis. In: *Interstitial Lung Disease*. 4th ed., M Schwarz , T King, Eds., BC Decker, Inc., 2003, pp. 418-434.

3. Steele, MP, Noble P. Genomics of Interstitial Lung Disease. In: *Genomic Medicine*. G Ginsburg, Ed., Blackwell Press, 2008, pp. 1110-1118.

Non-authored publications: (Faculty member formally acknowledged in the publication for his/her contributions.)

1. Clement A, Compisi J, Farmer SR, Brody JS. Constitutive expression of growth-related mRNAs in proliferating and nonproliferating lung epithelial cells in primary culture. *Proceed Natl Acad Sci USA*.87:318-322, 1990.

2. Alfred TF, Mercer RR, Thomas RF, Deng H, Auten RL. Brief 95% O_2 exposure effects on surfactant protein and mRNA in rat alveolar and bronchiolar epithelium. *Am J Physiol.*: *Lung Cell Mol Physiol*. 276(68, Part 1):L999-L1009. 1999.

Review Articles, Editorials, Letters:

1. **Steele MP**, Schwartz DA. Molecular Mechanisms in Progressive Idiopathic Pulmonary Fibrosis. *Annual Review of Medicine.*64:265-276, 2013.
2. Talbert JL, Schwartz DA, **Steele MP**: Familial Interstitial Pneumonia. *Clinical pulmonary medicine.* 21:120–127, 2014.
3. Kennedy GC, Barth NM, Walsh PS, Juang J, Pankratz DG, Choi Y, Fedorowicz GM, Anderson JD,Raghu G, Martinez FJ, Colby TV, Lynch DA, Brown KK, Groshong SD, Myers JL, Flaherty KR, **Steele MP**. Reply: Improving are for Patients with Interstitial Lung Disease: Using Machine Learning Requires Transparency and Reproducibility. *Ann Am Thorac Soc.* Dec 14, 2017.1864-65. PMID 29058451.

Abstracts (selected):

1. Joyce-Brady M., Rubins J, **Steele MP,** Dickey BF: G protein activation stimulates pulmonary alveolar type II cell surfactant secretion. *J Cell Biol.* 107a, 1988.

2. **Steele MP**, Kornfeld H, Brody JS: Immortalization of pulmonary alveolar type II cells by adenovirus 12SE1A. *Am Rev Respir Dis*. 254a, 1989.

3. **Steele MP,** Clement A. Alveolar type II epithelial cell lines generated by thermolabile SV 40 large T: Characterization at permissive and non-permissive temperatures. *Am Rev Respir Dis*. 824a, 1990.

4. Berrington WR, **Steele MP**, Levine RA: Regulation of growth-dependent and differentiation-specific genes in immortalized alveolar type II cells. *Am Rev Respir Dis*. 699a, 1990.

5. **Steele MP**, Brody JS, Reidel N. Isolation of genes specific for alveolar type II cells. *J Cell Biol.* 111:2470a, 1990.

6. **Steele MP**, Bennett V. Ankyrin expression in respiratory epithelium: evidence for ankyrin G-mediated linkage of cilia to the spectrin plasma membrane cytoskeleton. *Am Rev Respir Dis*. 1212a, 1995.

7. Palmer SM, **Steele MP,** Miralles AP, Lawrence CM, Peterson A, D'Amico TA, Davis RD, Tapson VP. Gastroesophageal reflux is an important cause of allograft dysfunction in lung transplant recipients. *J Heart Lung Transpl.* 18:64a, 1999.

8. Wood KA, Palmer SM, Govert JG, Baz MA, **Steele MP**, Davis RD, D'Amico TA, Tapson VF. Outcomes of lung transplant recipients with respiratory failure requiring mechanical ventilation. *Am J Respir Crit Care Med*. 1597:A739, 1999.

9. Wahidi MM, Speer MC, **Steele MP**, Brown KK, Schwartz MI, Schwartz DA. Familial pulmonary fibrosis in the USA. *Eur J Hum Genet*. 9:364, 2001.

10. Wahidi MM, Speer MC, **Steele MP,** Brown KK, Schwartz MI, Schwartz DA. Familial pulmonary fibrosis in the USA. *Am J Hum Genet.* 69(4): 285, 2001.

11. Palmer SM., Davis RD, Hadjiliadis D, Messier RH, **Steele MP**, Lawrence CM, Rea JB, Howell DN, Reinsmoen NL. Development of *de novo* antibodies to donor human leukocyte antigens is highly associated with bronchiolitis obliterans syndrome in lung transplant recipients. *J Heart Lung Transplant*. 21(1):75, 2002.

12. Hadjiliadis D, Cecilia C, Messier RH, Carlos G, **Steele MP**, Lianne SG, Davis RD, Tom WK, Hutcheon M, Palmer SM, Keshavjee S. Impact of lung transplant operation on bronchiolitis obliterans syndrome (BOS) in patients with chronic obstructive pulmonary disease (COPD). *J Heart Lung Transplant*. 21(1):77, 2002.

13. **Steele MP**, Davis RD, Messier RH, Pietrobon R, Alexander BD, Rea JB, Setliff KG, Palmer SM. Early colonization with pseudomonas in cystic fibrosis (CF) lung transplant recipients is associated with poor long-term survival. *J Heart Lung Transplant*. 21(1):107, 2002.

14. Hadjiliadis D, Carlos G, Chapparo C, Reinsmoen N, Singer LG, **Steele MP**, Waddell TK, Davis RD, Hutcheon M, Palmer SM, Kashavjee S. Pre-transplant PRA in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. *J Heart Lung Transplant*.21(1):108, 2002.

15. Patel VS, Davis RD, Messier RH, **Steele MP**, Hoopes CW, Palmer SM. Successful coronary artery revascularization and lung transplantation. *Am J Respir Crit Care Med*. 165(8):A392, 2002.

16. Palmer SM, Parekh P, Gullett EC, Babyak MA, Davis RD, **Steele MP**, Blumenthal JA. Depression is a significant predictor of perceived dyspnea and quality of life in patients awaiting lung transplantation. *Am J Respir Crit Care Med*. 165(8):A392, 2002.

17. Hadjiliadis D, Davis RD, **Steele MP**, Messier RH, Palmer SM. Development of bronchiolitis obliterans syndrome (BOS) and type of transplant are the major determinants of long-term survival in lung transplant recipients who survive at least six months post-transplant. *Am J Respir Crit Care Med*. 165(8):A403, 2002.

18. Palmer SM, Grinnan D, Reams BD, **Steele MP**, Davis RD. Oral Ganciclovir reduces the risk for posttransplant cytomegalovirus (CMV) infection in high risk, donor-positive/recipient-negative lung transplant patients. Presented at the *XIX International Congress of the Transplantation Society*. Miami, Florida, August 25-30, 2002.

19. Hadjiliadis D, **Steele MP**, Chaparro C, Singer LG, Messier RH, Waddell TK, Hutcheon MA, Davis RD, Tullis DE, Palmer SM, Keshavjee S. Survival of lung transplant recipients with cystic fibrosis (CF) harboring panresistant bacteria other than *B. cepacia*, compared to patients harboring sensitive bacteria. [Presented at the 23rd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, Vienna, Austria, April 9-12, 2003]. *J Heart Lung Transplant.* 22(18):S190, 2003.

20. Mohler K, Burnette A, Savik K, Hertz M, **Steele M,** Palmer S, Davis D, Reinsmoen N. Single cell detection of IFN-Gamma production identifies lung recipients at high risk for early immune complications. [Presented at the 23rd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, Vienna, Austria, April 9-12, 2003]. *J Heart Lung Transplant.* 22(18):S99, 2003.

21. Hadjiliadis D, Chaparro C, Messier RH, Gutierrez C, Waddell TK, **Steele MP**, Singer LG, Davis RD, Hutcheon MA, Palmer SM, Keshavjee S. Effects of transplant operation on survival after development of bronchiolitis oblierans syndrome (BOS) in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). [Presented at the 23rd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, Vienna, Austria, April 9-12, 2003]. *J Heart Lung Transplant.* 22(18):S92, 2003.

22. Hadjiliadis D, Chapparro C, Messier RH, Gutierrez C, Waddell TK, **Steele MP**, Singer LG, Davis RD, Hutcheon MA, Palmer SM, Keshavjee S. Impact of lung transplant operation on bronchiolitis oblierans syndrome (BOS) in patients with idiopathic pulmonary fibrosis (IPF). *Am J Transplantation*, 3:s5, A695, 2003. (presentation)

23. Hadjiliadis D, **Steele MP**, Govert JA, Davis RD, Palmer SM: Outcome of lung transplant recipients admitted to the Medical Intensive Care Unit (MICU). *Am J Transplantation*, 3:s5, A919, 2003.(presentation)

24. Mohler K, Savik K, Burnette A, Hertz M, **Steele M**, Palmer S, Davis RD, Reinsmoen N. Risk of rejection for lung recipients predicted using ELISpot to detect IFN-producing cells. Presented, American Society for Histocompatibility and Immunogenetics, Miami, Florida, October 28-November 1, 2003.(presentation)

25. Martinu T, **Steele MP**, Davis RD, Palmer SM. A ten year experience in pulmonary retransplantation: predictors of successful outcomes. *Am J Respir Crit Care Med*. 169(7):A99, 2004.(presentation)

26. Yang IV, Burch LH, **Steele MP**, Savov JD, Hollingsworth JW, Berman KG, Speer MC, Brown KK, Schwartz MI, Schwartz DA. Gene expression profiling distinguishes familial and non-familial forms of pulmonary fibrosis. *Proc Amer Thorac Soc*. A242, 2005. (presentation)

27. Palmer SM, Simsir SA, Lin SS, Reidy MF, **Steele, MP**, Eu PC, Davis RD, Babyak MA. Bilateral lung transplant offers superior survival independent of recipient age. *Proc Amer Thorac Soc*. A892, 2005. (presentation)

28. **Steele M,** Brown K, Wahidi M, Leslie K, Cool C, Sporn T, McAdams H, Speer M, Lynch D, Galvin J, Loyd J, Everett D, Schwarz M, Schwartz DA. The contrasting histopathologic and radiologic features of familial interstitial pneumonia (FIP) and idiopathic pulmonary fibrosis (S-IPF). *Proc Amer Thorac Soc*. 3:A242, 2006. (presentation)

29. Wise AL, **Steele MP**, Speer MC, Loyd JE, Brown KK, Herron A, Burch LH, Schwarz MI, Schwartz DA. Evidence for genetic heterogeneity in familial interstitial pneumonia (FIP). *Proc Amer Thorac Soc*., 175: 984 2007. (presentation)

30. Schwarz MI, Lori J., Silveira LJ, Seibold MA, Kummer N, Fingerlin TE, Murphy E, Cotter JD, Brown KK, **Steele MP**, Loyd JE, Lynch D, Bradford WZ, Szwarcberg J, du Bois RM, Schwartz DA. Non synonymous polymorphism in *MUC5AC* (Ala497Val) is associated with improved survival in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 181:A2494, 2010. (presentation)

31. Seibold MA, Lin J, Kervitsky D, Wescott J, Kummer N, Murphy E, Talbert J, Steele MP, Loyd JE, Brown KK, Schwarz MI, du Bois RM, Schwartz DA. The concentration of MUC5AC is higher in the air space of idiopathic pulmonary fibrosis (IPF) subjects and is associated with a disease susceptibility variant (Ala497Val) in *MUC5AC*. *Am J Respir Crit Care Med*. 181:A2493, 2010. (presentation)

32. Cosgrove GP, Groshong SD,Talbert J, Kervitsky D, Delaney R, Kummer N, Markin CR, Kidd R, Cool C, Seibold MA, **Steele MP**, Loyd JE, Brown KK, Schwartz DA, Schwarz MI. Familial Interstitial Pneumonia (FIP) is similar pathologically to Idiopathic Interstitial Pneumonia. *Am J Resp Crit Care Med*. 183:A2332, 2011. (presentation)

33. **Steele MP**, Brown KK, Loyd JE, Fingerlin T, Seibold MA, Kummer N, Kervitsky D, Talbert J, Delaney R, Markin CR, Kidd R, Schwarz MI, Schwartz DA. The environment influences the risk of developing Familial Interstitial Pneumonia. *Am J Respir Crit Care Med*. 183:A5690, 2011. (presentation)

34. Luna L, Yang IV, Cotter J, Talbert J, Leach S, Kidd R, Turner J, Kummer N, Boon K, Brown KK, Schwarz MI, Schwartz DA. Peripheral blood biomarkers differentiate extent of DLCO (but Not FVC) changes for Idiopathic Pulmonary Fibrosis (IPF). *Am J Respir Crit Care Med*. 183:A3558, 2011. (presentation)

35. **Steele MP** et al. Cohort Comparison Between Transbronchial Cryobiopsy and Surgical Lung Biopsy (SLB) in Patients Undergoing a Workup for Interstitial Lung Disease (ILD) from a Multicenter, Prospective Trial. *Am J Respir Crit Care Med*. 195:A3464, 2017.